

**REMARKS/ARGUMENTS**

This is in response to the official action dated September 25, 2007. Reconsideration in view of the following is respectfully requested.

An Abstract is now provided.

Claim 13 is canceled; therefore the rejection is moot. Claim 8 is amended to insert a correct dependence on claim 7, which therefore provides sufficient antecedent basis.

Claims 1, 2, 4, 7-9 stand rejected under 35 USC 102 as being anticipated by Ingkaninan. The reference relates to an on-line detection method for enzyme inhibitors and the inhibiting activity thereof. In the method of the reference, the inhibitor is detected by means of a mass spectrometer, but the detection of unreacted substrate, or of a modified substrate product, takes place by means of a UV-Vis spectrometer. As the reference does not teach detection of unreacted substrate, or of a modified substrate product by means of a mass spectrometer, it can not anticipate the claims.


The claims are rejected as being obvious under 35 USC 103 over Ingkaninan, and secondary references. However, neither of the secondary references cited makes up for the deficiency of Ingkaninan as set forth above. As it would not have been obvious to use mass

spectrometry to detect unreacted or modified substrate, the claims are allowable over this combination of references.

Early and favorable action is earnestly solicited.

Respectfully submitted,  
NORRIS MCLAUGHLIN & MARCUS, P.A.

By



Bruce S. Londa  
Reg. No. 33,531  
875 Third Avenue  
18<sup>th</sup> Floor  
New York, New York 10022  
Phone: (212) 808-0700  
Fax: (212) 808-0844